WVIC 2021 Booth #9

November 30-December 2, 2021

Advancing cancer and immunotherapy research with immunosequencing


The World Vaccine & Immunotherapy Congress (WVIC) is part of an award-winning series of conferences and exhibitions that are continuously growing becoming the largest and most established vaccine meetings of its kind across the globe

Adaptive is excited to be joining a panel discussion highlighting TCRs from discovery to therapeutics as well as giving a presentation on novel T-cell tests for the early detection of infectious disease and cancer. If you are attending WVIC in-person, we hope you’ll stop by booth #9 and connect.

Panel Discussion

TCRs from discovery to therapeutics

Cancer Immunotherapy, Room 3, Loews Coronado Bay Resort
Tuesday, November 30 | 3:10-4:10pm

Join us to learn about:

  • TCR target space advances – viral Ag, Neo Ag, Self Ag
  • What are the most effective targets? Optimization of TCR-based therapy
  • Improving TCR specificity and affinity to target
  • How can we improve protocols to ensure safety of any TCR going into clinic?
  • Optimal cell types for TCR therapy


Dr Stephen Schoenberger

Professor, Center for Cancer Immunotherapy

LaJolla Institute

Dr Leah Sibener

Co-Founder, Head of Therapeutic Discovery

3T Biosciences

Dr Sharon Benzeno

Chief Business Development Officer

Adaptive Biotechnologies

Dr Barbara Sennino

Senior Director, Tumor Immunology

PACT Pharma, Inc.


Novel T-cell tests for the early detection of infectious disease & cancer

Immune Monitoring & Translational Science, Room 2, Loews Coronado Bay Resort
Wednesday, December 1 | 12:10-12:40pm

Join us to learn about:

  • Adaptive’s bias-controlled and quantitative immunosequencing technology for sequencing of B- and T-cell receptors and it’s applications in infectious disease and cancer research.
  • Public T-cell receptor sequences and how they can be used as a biomarker for disease and are identified by combining immunosequencing with big data analytic techniques.
  • SARS-CoV-2 and how the use of public TCRs and TCR-antigen mapping data enables monitoring of recent or past infection, tracks response to vaccines, and aids in studying emerging variants.


Lance Baldo

Chief Medical Officer

Adaptive Biotechnologies

immunoSEQ Product Resources

Learn more about immunoSEQ Assay by downloading these helpful resources:

Contact us

Have Questions? Need to speak with someone?

Request information
Covid Icon Covid Icon
COVID-19 Applications

Learn how immunoSEQ® T-MAP™ COVID can help uncover the T-cell immune response in COVID-19.

Learn More
Library Icon Email Icon

Access technical documents for getting started with the immunoSEQ® Service product, grant writing support, and FAQs.

Learn More